FUSEN PHARM (01652) releases interim financial results, with a shareholder's net loss of 23.136 million yuan, narrowing by 37.37% year-on-year.

FUSEN PHARM(01652) released its interim results for the six months ending on June 30, 2025, with a revenue of 111 million yuan (RMB), a decrease of 43.31% compared to the same period last year. Shareholders' net loss was 23.136 million yuan, a decrease of 37.37% compared to the same period last year. Basic loss per share was 3 cents.